EVERSEPT PARTNERS LP
Q2 2023 Form 13-F
NEW YORK, NEW YORK
CIK 0001697013
· CRD 282358
· SEC-registered investment adviser
$1.2B Reported Value Total
EVERSEPT PARTNERS, L.P. reports 7 total accounts under management (AUM). There are 7 discretionary accounts valued at $1,671,022,000, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
3 funds
· $2.3B gross asset value
Hedge Fund: $2.3B
Source: Form ADV filed 2026-03-31
Reported value
$1.2B
Quarter over quarter
-2.8%
Holdings
66
Top-10 concentration
60.4%
Filing Structure
Reports holdings for
- TIFF ADVISORY SERVICES INC · File #028-11995 · Q4 2025 – Q4 2025 · declared by one filing
Key People
Form ADV owners & control persons
Kamran (nmn) Moghtaderi
MANAGING PRINCIPAL
Ron Avi Rosenstraus
CHIEF FINANCIAL OFFICER
Rishi Rasesh Shah
PRESIDENT
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2023 13F record
Q2 2023 13F filing summary
| Period of report | June 30, 2023 |
|---|---|
| Filed | August 14, 2023 |
| Form | 13F-HR |
| Reported value | $1.2B |
| Positions | 66 |
| Change in reported value | -16.6% |
| New positions | 17 |
| Exited positions | 9 |
| Position turnover | 34.7% |
| Top-10 concentration | 60.4% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
115 | $1.9B |
|
Q1 2026 13F
Filed May 15, 2026
|
104 | $1.9B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
103 | $2.0B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
83 | $1.5B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
67 | $1.1B |
|
Q1 2025 13F
Filed May 15, 2025
|
55 | $984.7M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
62 | $1.1B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
65 | $1.5B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
72 | $1.5B |
|
Q1 2024 13F
Filed May 15, 2024
|
68 | $1.5B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
55 | $1.1B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
61 | $1.2B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
66 | $1.2B |
|
Q1 2023 13F
Filed May 15, 2023
|
58 | $1.4B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
62 | $1.1B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
60 | $1.8B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
65 | $2.1B |
|
Q1 2022 13F
Filed May 16, 2022
|
76 | $1.3B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
90 | $2.1B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
88 | $1.4B |
15 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | QQQ P INVESCO QQQ TR | $129.3M | 10.81% |
| 2 | NTRA NATERA INC | $117.5M | 9.82% |
| 3 | GSK GSK PLC | $103.8M | 8.68% |
| 4 | SPY P SPDR S&P 500 ETF TR | $102.0M | 8.52% |
| 5 | TEVA TEVA PHARMACEUTICAL INDS LTD | $57.7M | 4.83% |
| 6 | UTHR UNITED THERAPEUTICS CORP DEL | $57.5M | 4.81% |
| 7 | HZNP HORIZON THERAPEUTICS PUB L | $48.9M | 4.09% |
| 8 | SNDX SYNDAX PHARMACEUTICALS INC | $45.8M | 3.83% |
| 9 | CYH COMMUNITY HEALTH SYS INC NEW | $32.0M | 2.68% |
| 10 | TECH BIO-TECHNE CORP | $28.0M | 2.34% |
| 11 | VERA VERA THERAPEUTICS INC | $27.9M | 2.34% |
| 12 | INSP INSPIRE MED SYS INC | $26.8M | 2.24% |
| 13 | CLDX CELLDEX THERAPEUTICS INC NEW | $26.7M | 2.23% |
| 14 | DHR DANAHER CORPORATION | $24.8M | 2.08% |
| 15 | HCA HCA HEALTHCARE INC | $24.5M | 2.05% |
| 16 | ILMN ILLUMINA INC | $23.3M | 1.94% |
| 17 | ICLR ICON PLC | $17.9M | 1.5% |
| 18 | BCRX BIOCRYST PHARMACEUTICALS INC | $16.7M | 1.4% |
| 19 | AMRX AMNEAL PHARMACEUTICALS INC | $16.3M | 1.36% |
| 20 | CTLT CATALENT INC | $15.5M | 1.29% |
Values as reported on the Q2 2023 Form 13F. Every position is in the holdings table below.